Sign in
Taking peopleNo phase

MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK

Key facts

Who runs it
Insel Gruppe AG, University Hospital Bern
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
56 people, planned
Started
1 Jun 2026
Expected to end
31 Dec 2027
Type of study
Observational, 2 groups
Record updated
2 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Septic shock:
  • New onset (<24h) of septic shock diagnosis according to Sepsis-3 definition
  • (suspected) infection
  • Vasopressors required to maintain mean arterial pressure ≥65mm Hg (despite adequate fluid resuscitation)
  • Serum lactate level > 2mmol/L
  • Minimum age of 18 years
  • Expected length of stay >48h
  • Written consent from an independent physician; Critically ill:
  • Patients on mechanical ventilation (MV) in the ICU without an admission diagnosis of sepsis/septic shock according to Sepsis-3 definition
  • Minimum age of 18 years
  • Expected length of stay >48h
  • Written consent from an independent physician

Who cannot take part

  • Patients with known; Pre-existing congenital or acquired severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS) or; current immunosuppressive therapy (immunosuppressive biologicals or active lymphocyte therapy e.g. endoxan, rituximab or corticosteroid use at a dose > 10 mg/day equivalent of prednisone. However, acute corticosteroid treatment of a relative adrenal insufficiency using a maximum hydrocortisone dose of 200 mg/day is accepted
  • Age < 18 years
  • Patients known not to speak German or French

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Sepsis-induced immunosuppression (SIS) is a common complication in patients with septic shock. Reduced expression of Human leukocyte antigen isotype DR (HLA-DR) on circulating monocytes is a marker for SIS and correlates with risk of secondary infections and mortality. The miRSep study aims to improve the understanding of early microRNA (miRNA) mediated changes in HLA-DR on monocytes in patients with septic shock.

The 2 groups in the trial

  • Septic shock

    Patients in ICU with diagnosed septic shock

  • Critically ill patients

    Critically ill patients in ICU without sepsis diagnosis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
MIRSEP - MIRNA QUANTIFICATION IN PATIENTS WITH SEPTIC SHOCK
Record updated
2 June 2026